The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.941832
Abstract: Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific activity and has waste disposal advantages over the first generation… read more here.
Keywords: neuroendocrine tumors; added 177; prrt; treatment ... See more keywords